Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2023 Earnings Conference Call February 15, 2024 8:00 AM ET
Company Participants
Chris Taylor - Vice President, Investor Relations and Corporate Communications
Brian Goff - Chief Executive Officer
Cecilia Jones - Chief Financial Officer
Tsveta Milanova - Chief Commercial Officer
Sarah Gheuens - Chief Medical Officer, Head of R&D
Conference Call Participants
Chris Raymond - Piper Sandler
Danielle Brill - Raymond James
Gregory Renza - RBC Capital Markets
Tess Romero - JP Morgan
Greg Harrison - Bank of America
Divya Rao - TD Cowen
Operator
Good morning. And welcome to the Agios Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that this call is being recorded at Agios’ request.
I would now like to turn the call over to Chris Taylor, Vice President, Investor Relations and Corporate Communications for Agios. Please go ahead.
Chris Taylor
Thank you, operator. Good morning, everyone and welcome to Agios’ conference call and webcast to discuss fourth quarter and full year 2023 financial results and recent business highlights. You can access slides for today’s call by going to the Investors section of our website, agios.com.
On today’s call, I am joined by our Chief Executive Officer, Brian Goff; Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, Chief Financial Officer.
Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may
- Read more current AGIO analysis and news
- View all earnings call transcripts